X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
breast cancer (11) 11
humans (10) 10
oncology (10) 10
chemotherapy (9) 9
female (9) 9
index medicus (9) 9
middle aged (9) 9
adult (7) 7
breast neoplasms - drug therapy (7) 7
cancer (7) 7
care and treatment (7) 7
hematology, oncology and palliative medicine (7) 7
aged (6) 6
antimitotic agents (6) 6
antineoplastic agents (6) 6
metastasis (6) 6
survival (6) 6
breast neoplasms - pathology (5) 5
cancer therapies (5) 5
trastuzumab (5) 5
analysis (4) 4
bevacizumab (4) 4
clinical trials (4) 4
disease-free survival (4) 4
neoplasm staging (4) 4
product development (4) 4
studies (4) 4
antibodies, monoclonal, humanized - administration & dosage (3) 3
antineoplastic combined chemotherapy protocols - administration & dosage (3) 3
antineoplastic combined chemotherapy protocols - adverse effects (3) 3
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
breast neoplasms - mortality (3) 3
breast neoplasms - secondary (3) 3
capecitabine (3) 3
fluorouracil - administration & dosage (3) 3
kaplan-meier estimate (3) 3
paclitaxel (3) 3
prognosis (3) 3
receptor, erbb-2 - genetics (3) 3
research (3) 3
taxoids - administration & dosage (3) 3
therapy (3) 3
trial (3) 3
adjuvant treatment (2) 2
aged, 80 and over (2) 2
angiogenesis inhibitors (2) 2
antibodies, monoclonal, humanized - adverse effects (2) 2
antibodies, monoclonal, humanized - therapeutic use (2) 2
breast (2) 2
breast neoplasms - genetics (2) 2
breast neoplasms - metabolism (2) 2
chemotherapy, adjuvant (2) 2
circulating tumor-cells (2) 2
combination (2) 2
combined modality therapy (2) 2
consent (2) 2
deoxycytidine - administration & dosage (2) 2
deoxycytidine - analogs & derivatives (2) 2
development and progression (2) 2
fluorouracil - analogs & derivatives (2) 2
follow-up (2) 2
follow-up studies (2) 2
medicine (2) 2
multicenter (2) 2
oncology, experimental (2) 2
open-label (2) 2
pathological response (2) 2
patients (2) 2
predictive value of tests (2) 2
progression (2) 2
proportional hazards models (2) 2
receptor, erbb-2 - analysis (2) 2
receptor, erbb-2 - metabolism (2) 2
research article (2) 2
safety (2) 2
time factors (2) 2
treatment outcome (2) 2
adenocarcinoma (1) 1
adjuvant chemotherapy (1) 1
adolescent (1) 1
analgesics (1) 1
angina pectoris (1) 1
angiogenesis (1) 1
antigens, neoplasm - metabolism (1) 1
antineoplastic agents - administration & dosage (1) 1
antineoplastic agents - adverse effects (1) 1
antineoplastic agents - therapeutic use (1) 1
anxiety (1) 1
aromatase (1) 1
aromatase inhibitors - therapeutic use (1) 1
asthenia - chemically induced (1) 1
bevacizumab - administration & dosage (1) 1
bevacizumab - adverse effects (1) 1
biology and life sciences (1) 1
biomarkers, tumor - blood (1) 1
body image (1) 1
bone marrow (1) 1
bone marrow cells - metabolism (1) 1
bone marrow cells - pathology (1) 1
bone marrow neoplasms - secondary (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 4, pp. 406 - 414
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 8, pp. 741 - 748
Summary Background Since 2005, 12 months of adjuvant trastuzumab has been the standard treatment for patients with HER2-positive early-stage breast cancer.... 
Hematology, Oncology and Palliative Medicine | ONCOLOGY | FOLLOW-UP | CHEMOTHERAPY | Breast Neoplasms - surgery | Predictive Value of Tests | Breast Neoplasms - secondary | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Young Adult | Breast Neoplasms - chemistry | Antibodies, Monoclonal, Humanized - administration & dosage | Neoplasms, Second Primary | Time Factors | Antineoplastic Agents - adverse effects | Aged, 80 and over | Mastectomy | Adult | Female | Chemotherapy, Adjuvant | France | Heart Diseases - chemically induced | Radiotherapy, Adjuvant | Antibodies, Monoclonal, Humanized - adverse effects | Drug Administration Schedule | Early Detection of Cancer | Kaplan-Meier Estimate | Neoplasm Recurrence, Local | Proportional Hazards Models | Treatment Outcome | Breast Neoplasms - drug therapy | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Breast Neoplasms - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - mortality | Aged | Infusions, Intravenous | Receptor, ErbB-2 - analysis | Trastuzumab | Antimitotic agents | Care and treatment | Clinical trials | Breast cancer | Product development | Antineoplastic agents | Cancer
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 13, pp. 1493 - 1502
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 4, pp. 375 - 384
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 5, pp. 600 - 611
Journal Article
by Pivot, Xavier and Romieu, Gilles and Debled, Marc and Pierga, Jean-Yves and Kerbrat, Pierre and Bachelot, Thomas and Lortholary, Alain and Espié, Marc and Fumoleau, Pierre and Serin, Daniel and Jacquin, Jean-Philippe and Jouannaud, Christelle and Rios, Maria and Abadie-Lacourtoisie, Sophie and Venat-Bouvet, Laurence and Cany, Laurent and Catala, Stéphanie and Khayat, David and Gambotti, Laetitia and Pauporté, Iris and Faure-Mercier, Celine and Paget-Bailly, Sophie and Henriques, Julie and Grouin, Jean Marie and Piprot, C and Cals, L and Chaigneau, L and Demarchi, F and N'Guyen, T and Stein, U and Villanueva, C and Bréau, JL and Chouahnia, AK and Saintigny, P and Boué, F and deSaint-Hilaire, P and Guimont, I and Grossat, N and Valenza, B and Lévy, E and Médioni, J and Delbaldo, C and Grenier, J and Pouessel, D and Lavau-Denès, S and Falandry, C and Fournel-Fédérico, C and Freyer, G and Tartas, S and Trillet-Lenoir, V and Bons, F and Auclerc, G and Chièze, S and Raban, N and Tournigand, C and Trager-Maury, S and Bousquet, G and Cuvier, C and Giacchetti, S and Hocini, A and LeMaignan, C and Misset, JL and Avenin, D and Beerblock, C and Gligorov, J and Rivera, P and Roché, H and Bougnoux, P and Hajjaji, N and Capitain, O and Delva, R and Maillart, P and Soulié, P and Bonnefoi, H and Durand, M and Madranges, N and Mauriac, L and Chollet, P and Dillies, AF and Durando, X and Ferrière, JP and Mouret-Reynier, C and Nabholtz, JM and Van Praagh, I and Cottu, P and Diéras, V and Durieux, A and Galotte, M and Girre, V and Henry, S and Iurisci, I and Jouve, M and Laurence, V and Mignot, L and Piperno-Neumann, S and Tresca, P and Coudert, B and Ferrant, E and Mayer, F and Vanneuville, AC and ... and PHARE Trial Investigators and PHARE trial investigators
The Lancet, ISSN 0140-6736, 06/2019, Volume 393, Issue 10191, pp. 2591 - 2598
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 1, pp. 64 - 71
Journal Article
Journal Article